Myelodysplastic Syndromes
Myelodysplastic Syndromes
Myelodysplastic Syndromes
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
8% blasts (CD34, CD117)<br />
75% monocytic cells<br />
Remember: promonocytes are blast equivalents<br />
WHO Classification-Based Prognostic<br />
Scoring System for MDS<br />
Prognostic Variable Score Value<br />
*Karyotype definitions same as IPSS<br />
*RBC transfusion dependency defined<br />
as at least 1 RBC transfusion every 8<br />
weeks over a period of 4 months.<br />
0 1 2 3<br />
WHO category RA, RARS,5q- RCMD RAEB-1 RAEB-2<br />
Karyotype Good Intermediate Poor<br />
Transfusion* No Regular<br />
Risk groups Score AML<br />
Very low 0 3-6%<br />
Low 1 14-24%<br />
Intermediate 2 33-48%<br />
High 3-4 54-63%<br />
Very high 5-6 84-100%<br />
Median follow up 27-30 months<br />
Malcovati L, et al. Time-Dependent Prognostic Scoring System for Predicting Survival<br />
and Leukemic Evolution in <strong>Myelodysplastic</strong> <strong>Syndromes</strong>. J. Clin. Oncol. 2007, 25: 3503-3510.<br />
International Prognostic Scoring System (IPSS)<br />
Prognostic<br />
variable<br />
Score Value<br />
0 0.5 1.0 1.5 2.0<br />
BM blasts (%) 3 abnormalities) or<br />
abnormalities of chromosome 7<br />
Intermediate : other abnormalities<br />
Cytopenias defined as:<br />
•Hemoglobin
Change language